> **Layer 1** · Medicine & Health Sciences · `H11-ADDICTOLOGIA`

## Purpose
The `H11-ADDICTOLOGIA` agent provides specialized neurobehavioral, pharmacokinetic, and clinical decision support for substance use disorders (SUD) and behavioral addictions. It models reward circuitry dynamics, receptor occupancy, withdrawal kinetics, relapse risk trajectories, and evidence-based pharmacotherapies including Medication-Assisted Treatment (MAT / MOUD).

By bridging molecular neuroadaptations (e.g., mesolimbic dopamine downregulation, CRF/dynorphin stress hyperactivation) with clinical bedside metrics (COWS, CIWA-Ar), this agent empowers the H11 substrate to formulate safe detoxification regimens, prevent precipitated withdrawal, optimize agonist/antagonist maintenance, and anticipate acute relapse vulnerabilities.

## Technical Deep-Dive
At its computational core, `H11-ADDICTOLOGIA` executes a multi-compartment neurochemical and behavioral simulation framework:

1. **Mesocorticolimbic & Allostatic Dynamics Engine**:
   - Models the transition from positive reinforcement (impulsivity, ventral striatum/NAc dopamine surges) to negative reinforcement (compulsivity, dorsal striatum habit formation, extended amygdala allostatic load).
   - Tracks tonic vs. phasic dopamine firing rates and allostatic setpoint drift as a function of substance exposure frequency and potency.

2. **Receptor Occupancy & PK/PD Interaction Matrix**:
   - Opioidergic dynamics: Full agonists (morphine, heroin, methadone, fentanyl) vs. partial agonists (buprenorphine with high receptor affinity, $K_i \approx 0.219\text{ nM}$) vs. competitive antagonists (naloxone, naltrexone).
   - Models lipophilic tissue sequestration (e.g., fentanyl adipose depots) and computes precise clearance curves to avert precipitated withdrawal during buprenorphine induction.
   - GABAergic/Glutamatergic balance: Quantifies GABA-A receptor uncoupling and NMDA upregulation in chronic ethanol and benzodiazepine dependence, projecting delirium tremens and seizure risk curves.

3. **Dynamic Withdrawal Progression & Scoring**:
   - Integrates Clinical Opiate Withdrawal Scale (COWS) and Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) time-series.
   - Employs Markov state-transition models to forecast autonomic instability, tremor velocity, and psychomotor agitation.

4. **Relapse Risk Stratification & Survival Modeling**:
   - Implements a multi-factorial survival model incorporating craving intensity, cue reactivity, autonomic dysregulation (HRV vagal tone), sleep debt, and stress biomarkers.
   - Identifies high-risk temporal windows (e.g., 72 hours post-discharge, post-relapse guilt loops).

## Architecture

### Input Contract
| Field | Type | Description |
|-------|------|-------------|
| `use_history` | `List[SubstanceUseRecord]` | Detailed log of psychoactive substances, doses, routes, chronicity, and last use. |
| `neuro_baseline` | `NeurochemicalBaseline` | Estimated receptor down-regulation, baseline tone, and allostatic load index. |
| `withdrawal_inputs` | `WithdrawalScore` | Real-time clinical withdrawal assessments (COWS, CIWA-Ar, autonomic vitals). |
| `craving_cues` | `List[RelapseTriggerType]` | Active environmental, affective, or somatic triggers. |

### Output Contract
| Field | Type | Description |
|-------|------|-------------|
| `withdrawal_trajectory` | `DetoxificationProtocol` | Tailored detoxification schedule, taper curve, and safety monitoring rules. |
| `mat_protocol` | `MATInductionPlan` | Specific MAT initiation strategy (standard vs. Bernese microdosing), titration steps. |
| `relapse_risk_profile` | `RelapseRiskProfile` | 30-day lapse hazard curve, primary risk drivers, and protective intervention targets. |
| `polysubstance_synergy` | `Dict[str, Any]` | Respiratory depression risk, toxicological interactions, and naloxone rescue parameters. |

### State Schema
The agent maintains an `AddictionNeuroStateMatrix` per patient tracking:
- Target receptor availability ($\mu$-opioid, $\text{GABA}_A$, $\text{NMDA}$, $\text{DAT}$, $\text{CB}_1$).
- Current allostatic setpoint displacement ($\Delta S_{\text{allo}}$).
- Tolerance index ($\theta_{\text{tol}}$) and sensitized incentive salience factor ($\sigma_{\text{sal}}$).
- Lipophilic tissue burden ($C_{\text{adipose}}$).

## Dependencies
### Upstream (depends on)
- `H11-PHARMACOLOGIA`: Provides foundational receptor affinity constants, hepatic clearance (CYP2D6, CYP3A4), and half-life parameters.
- `H11-NEUROLOGIA`: For electrophysiological, autonomic, and central nervous system integrity models.
- `H11-PSYCHIATRIA`: For dual-diagnosis comorbidity mapping (MDD, PTSD, Bipolar, ADHD).
- `H11-TOXICOLOGIA`: For acute overdose management and xenobiotic screening analytics.

### Downstream (feeds into)
- `H11-HEPATOLOGIA`: For hepatic metabolism constraints in cirrhosis/hepatitis C during pharmacotherapy selection.
- `H11-CARDIOLOGIA`: For QTc prolongation monitoring (e.g., high-dose methadone) and autonomic arrhythmia risk.
- `H11-EMERGENCYMED`: For rapid naloxone titration and severe withdrawal crisis stabilization.
- `H11-PUBLICHEALTH`: For harm-reduction surveillance, overdose alert networks, and naloxone distribution logistics.

## Failure Modes
- **Precipitated Withdrawal Induction**: Misjudging residual lipophilic synthetic opioids (fentanyl) and triggering violent receptor displacement upon buprenorphine administration.
- **Post-Detoxification Loss of Tolerance**: Underestimating fatal overdose vulnerability when patients relapse after a period of abstinence.
- **Delirium Tremens Onset Window Miss**: Failing to anticipate delayed peak withdrawal in long half-life benzodiazepine or heavy alcohol dependence.
- **Polysubstance Respiratory Collapse**: Overlooking synergistic central respiratory depression between sub-threshold doses of opioids, benzodiazepines, and alcohol.

## Performance Characteristics
- Latency: <35ms for acute withdrawal risk and overdose rescue calculation; <120ms for multi-compartment PK/PD MAT induction modeling.
- Memory Footprint: ~38MB for substance interaction graphs and receptor binding affinity lookup tables.

## Research References
1. Koob, G. F., & Volkow, N. D. (2016). Neurobiology of addiction: a neurocircuitry analysis. *The Lancet Psychiatry*, 3(8), 760-773.
2. Volkow, N. D., Boyle, M., & Blanco, C. (2020). Medication-assisted treatment for opioid use disorder. *JAMA*, 324(4), 337-338.
3. Strang, J., et al. (2020). Loss of tolerance and overdose mortality among opioid-dependent individuals. *Addiction*, 115(5), 908-917.
4. Anton, R. F., et al. (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study. *JAMA*, 295(17), 2003-2017.
5. Rozycki, A. T., et al. (2022). Micro-induction of buprenorphine/naloxone (Bernese method) in acute care: clinical outcomes and best practices. *Journal of Addiction Medicine*, 16(3), 320-327.

## Implementation Notes
- Use stiff differential equation solvers (e.g., implicit backward differentiation) for high-affinity receptor displacement kinetics.
- Maintain absolute separation of sensitive SUD records in accordance with 42 CFR Part 2 and HIPAA privacy regulations.
